

Improving Lung Cancer Outcomes Through the MDT

Dr Will Ricketts

Consultant Chest Physician, Barts Health NHS Trust




@TB_Doc





Our Improvement Journey





Improving the MDT



Background

- Barts Heart Centre
Respiratory Medicine
- Barts Cancer Centre
- London Cancer
- CRUK
- Learning from each other



Challenges

- Nationally:
 - Increasing patient numbers
 - NHS budget demands
 - Ensuring and *demonstrating*, safe and effective care
- Barts Health:
 - Outdated, unreliable video conferencing equipment
 - On-going review of resources (staff)
 - Large number of cancer MDTs (hub and spoke)
 - Uniquely large number of non-cancer (especially Cardiac) MDTs
 - Tertiary centre – Discuss patients never seen by BH clinician



Getting Started ...



Questionnaire

- 5 Key Areas:
 - Referral Process and pre-MDT preparation
 - Discussion
 - Documentation
 - Dissemination and actioning of Outcomes
 - Governance

Quality Improvement Conversation

Setting MDT Quality Improvement

The Referral Process

Headlines

- Referrals
 - 80% by email
 - 60% on proforma

Deadlines

- 55% have a deadline – 70% ≤1-2 days
- Many unaware of own MDT deadline
- General feeling that attitudes to deadline are too relaxed

Imported Imaging and Pathology

- 1/3 reliant on external imaging and 25% reliant on external path
- Approx. 1/3 delayed due to this not being available

Time commitment:

- 2.1 hours spent prepping MDT/week
- 2.9 hours spent in MDTs/week

The MDT Discussion

Headlines

- Majority felt language usage was clear and consistent
- Remote access approx. 50:50
- Generally felt not to work well, usually due to AV problems

Recording Decisions

Headlines

- 40% Clinician
 - 40% Consultant
 - 45% Registrar
 - 5% CNS
- 20% Admin
- 40% Mixture

- 13% Document live on CRS
- 80% Document contemporaneously but uploaded later
- Majority have proforma, but only approx. half have prompts on proforma

Dissemination and Ac Outcomes

Headlines

- 75% proactively feedback, but 25% assume that referrer will review EPR/CRS without being prompted
- 70% of feedback within 24 hours
- 70% led by MDT coordinator
- Mixture of who enacts outcomes – Coordinators, Clinicians and Referrers
- Generally felt to be clear as to whose responsibility enacting outcomes is, but some concerns raised about ambiguity

MDT Governance

Headlines	Questions
<ul style="list-style-type: none">90% keep a register30% have no definition of quoracyNon-quoracy almost always leads to deferral of cases45% have no review process for their MDT	<ul style="list-style-type: none">What should happen to a register?Does this pose a clinical risk?Clearly felt to be important, if so why no definition in 30%?Is this managed differently for patients on timed e.g. 62 day pathways?Is this acceptable or should at least annual review be compulsory?How do MDTs review the safety, efficiency and clinical effectiveness of their decisions?Can service changes be justified with any evidence from MDTs?

Issues Highlighted

Referral Process

- Lack of awareness of Deadlines
- Time taken to prepare – Average 5 hours

MDT Discussion

- AV Equipment

Documentation

- No single system
- Proforma use and design

Dissemination & Actioning Outcomes

- Potential for Ambiguity

Governance

- Definition of Quoracy
- Review process




Development of 10 Key Principles

1. MDTs should have a designated Lead and Coordinator, both of whom should be job planned
2. A deadline for case submission should be set and actively enforced
3. External deadlines should be set to allow time for importing pathology and/or radiology
4. Cases should be submitted on a bespoke proforma, where discussion and outcomes should also be recorded
5. MDT agenda structured to maximise efficiency
6. MDTs should not run for longer than 2 hours, without a 15min+ break
7. Documentation should be on a proforma that encourages full discussion and data collection (audit & trials), plus patient preference
8. CRS should be used for real time documentation and have live MDT review
9. A member of the MDT must be responsible for disseminating MDT outcomes in a timely manner
10. MDTs must keep a register, have a definition of quoracy and know how to manage non-quoracy



Self Assessment



NHS
Barts Health
NHS Trust

Barts Health NHS Trust
MDT Review Checklist
Improving the safety and level of care we deliver to our MDT patients

Dr Edward Rowland, Consultant Cardiologist, Medical Director St Bartholomew's Hospital
Dr William Ricketts, Consultant Chest Physician, Project Lead Clinician
Ms Henna Roberts, Senior Improvement Manager, Project Lead Facilitator
10/24/2018

Version 1 – Last updated November 2018



MDT Review Checklist

This MDT Review Checklist is the result of a Trust improvement project to improve the safety and level of care we deliver to our MDT patients. It also aimed to share best practice across all MDT specialties (cancer and non-cancer). Out of this work came 10 MDT guidelines (see Appendix 1). This checklist will aid MDTs assess themselves against these 10 MDT guidelines. It is intended to be a quick and easy tool. If there are any additional sheets where needed, then these are on the checklist. Additional sheets can be found on the additional sheets where needed. Where an MDT is not issue and resulting action or escalation they will be in the 'Not Applicable' section. These actions must then be fed into the local safety action plan.

All MDTs must use the MDT Review Checklist and undertake (recommended) which must be minuted. The agenda for 10 MDT guidelines as well as relevant local and national completed checklists should be registered with the TRU (details). Resulting actions and escalations should link to Appendix 2. Annual peer review is also recommended. Surveillance process or more informally such as internal action.

Ideally this form should be completed with all MDT members and allow discussion. At a minimum it should be completed together.

Name of MDT
Clinical Lead(s)
MDT Coordinator(s)
Day and Timings of MDT
Frequency
Room/Venue
Average number of patients discussed during MDT
Is video or tele conferencing used? Yes
This MDT is the Only meeting Hub
If Hub, please state where the spokes are based
If spokes, please state where the hub is based

1
2

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

Documentation

Barts Thorax Centre Lung Cancer MDT Proforma


Name:	DOB:	Number:							
Consultant:	Added by:	Presenter:							
*Date for Discussion:		For Diagnostic MDT Only Cancer <input type="checkbox"/> Non-Cancer <input type="checkbox"/>							
Breach date (to be completed by MDT Coordinator): Tuesdays = Decision to treat MDT – Cases must be submitted by 16:00 Friday Fridays = Diagnostic and General Respiratory MDT – Cases must be submitted by 13:00 Thursday It is expected that the plan will be enacted by the referring team unless specifically stated otherwise.									
*Case summary									
**Smoking Status	**WHO Performance Status								
**FEV1	**FEV1 % predicted								
FVC	**TLCO % Predicted								
**Relevant Social Hx Holistic Needs and Patient Preference									
Next Follow Up	Breach Date								
*Question for MDT									
* If these fields are not completed the case will not be discussed									
** If these field are not completed for suspected cancer cases the case will not be discussed									
MDT Discussion:									
Staging:	CT	T	N	M	Pathological	PT	PN	PI	R
	PET	T	N	M	Combined	T	N	M	
Pathology result:									
Advice/Plan:									
Plan B:									
Relevant Research Studies:									
Responsible Clinician:									

Form for repeat discussion:

Name:	Number:								
Consultant:	Added by:	Presenter:							
Date for Discussion: Date of previous discussion: Tuesdays = Decision to treat MDT – Cases must be submitted by 16:00 Friday Fridays = Diagnostic and General Respiratory MDT – Cases must be submitted by 13:00 Thursday It is expected that the plan will be enacted by the referring team unless specifically stated otherwise.									
<u>Update since last discussion (include any incomplete mandatory fields):</u>									
Question for MDT (if this is not completed with a clear question the case will not be discussed):									
Next Follow Up	Breach Date								
MDT Discussion:									
Staging:	CT	T	N	M	Pathological	PT	PN	PI	R
	PET	T	N	M	Combined	T	N	M	
Pathology result:									
Advice/Plan:									
Plan B:									
Relevant Research Studies:									
Responsible Clinician:									

Time to Treatment 2020

Mean 6th fastest, Median 3rd fastest



CWT Target				Apr-21	May-21	Jun-21	Jul-21	Aug-21	Sep-21	Oct-21	Nov-21	Dec-21
BH	Two Week Wait	93%	Seen	44	62	55	58	32	59	64	54	61
			Breach	4.0	4.0	4.0	17.0	5.0	15.0	13.0	9.0	7.0
			(%)	90.9%	93.5%	92.7%	70.7%	84.4%	74.6%	79.7%	83.3%	88.5%